Repatha Rebound Effects When Stopping: What the Evidence Actually Shows

What does rebound mean for a PCSK9 antibody?

Rebound means the original problem comes back worse after a drug is removed, an overshoot above the pre-treatment baseline rather than a return to it.

For evolocumab, the question is whether LDL rises above its pre-treatment level after the drug is gone. Evolocumab binds PCSK9, the protein that promotes degradation of LDL receptors on liver cells; blocking that binding leaves more LDL receptors available to clear LDL from the blood [1]. The label describes no withdrawal reaction [1].

What the Repatha label says

Repatha has no boxed warning. Its one Warning and Precaution is hypersensitivity reactions including angioedema; the label says to stop treatment and treat if serious symptoms occur [1]. The contraindication is a history of a serious hypersensitivity reaction to evolocumab or any excipient [1].

For adults at increased cardiovascular risk or with hypercholesterolemia, the labeled regimens are 140 mg every 2 weeks or 420 mg once monthly, given under the skin [1]. The label describes a 420 mg dose as three 140 mg injections given within 30 minutes [1].

What FOURIER and VESALIUS-CV measured

FOURIER randomized 27,564 adults with atherosclerotic cardiovascular disease and LDL of 70 mg/dL or higher on statin therapy to evolocumab or placebo [2]. At 48 weeks, LDL fell from a median 92 mg/dL to 30 mg/dL, a 59% reduction versus placebo [2]. The primary composite of cardiovascular death, myocardial infarction, stroke, unstable angina hospitalization, or coronary revascularization occurred in 9.8% versus 11.3% (HR 0.85, 95% CI 0.79 to 0.92) over a median 26 months [1][2]. Cardiovascular death (HR 1.05) and all-cause death (HR 1.04) did not differ from placebo [1][2].

VESALIUS-CV randomized 12,257 adults with atherosclerosis or diabetes and no prior myocardial infarction or stroke, LDL of 90 mg/dL or higher, to evolocumab 140 mg every 2 weeks or placebo [3]. Over a median 4.6 years, 3-point MACE occurred in 6.2% versus 8.0% at 5 years (HR 0.75, 95% CI 0.65 to 0.86), and 4-point MACE in 13.4% versus 16.2% (HR 0.81, 95% CI 0.73 to 0.89) [3].

Both trials compared evolocumab with placebo while treatment continued. Neither randomized people to stop the drug and measured LDL or events afterward [2][3].

How long does evolocumab stay in the body?

After a subcutaneous dose, median peak concentration occurs at 3 to 4 days, absolute bioavailability is about 72%, and the effective half-life is 11 to 17 days [1]. Trough levels approach steady state by 12 weeks [1]. The drug is eliminated by target binding and proteolysis [1].

The label also gives onset data: maximum LDL reduction occurs by 2 weeks after a 140 mg dose and by 3 weeks after 420 mg [1]. These describe the response after starting treatment, not an LDL curve after stopping.

What about missing a dose rather than stopping?

The label covers late doses separately from discontinuation. For a missed dose within 7 days, it says to give the dose and resume the original schedule. If the dose is more than 7 days late, the label says to wait for the next scheduled dose on the every-2-week schedule, or to give the dose and start a new schedule on the monthly regimen [1].

What safety findings are listed?

In eight pooled controlled trials, injection site reactions occurred in 3.2% on evolocumab versus 3.0% on placebo, and hypersensitivity reactions in 5.1% versus 4.7% [1]. In a 52-week placebo-controlled trial of 420 mg monthly, nasopharyngitis (10.5% vs 9.6%) and upper respiratory tract infection (9.3% vs 6.3%) were the most common adverse reactions [1].

Immunogenicity is low: 0.3% (48 of 17,992) of adults developed binding antibodies, none neutralizing, with no evidence of an effect on pharmacokinetics, response, or safety [1].

What the trials do not show

FOURIER and VESALIUS-CV did not measure LDL after evolocumab was stopped [2][3]. The shape of the return, whether LDL goes back to baseline, above it, or stays partly lowered, is therefore not shown in them. The same applies to planned drug holidays and to cardiovascular risk right after the last injection. The lower event rates they report describe outcomes during follow-up on treatment [2][3].